Compound (R)-23a, a dual DNMT1/HDAC inhibitor, has shown potent inhibition of both targets, effectively reactivating tumor suppressor genes and suppressing tumor growth in xenograft models [206]. This evidence concerns the gene HDAC9 and neoplasm.